S-1/A: Option Therapeutics Launches IPO for Liver Disease Drug BIV201

Option Therapeutics Inc., a BioVie subsidiary, is launching its initial public offering to fund the Phase 3 clinical trial of BIV201, an investigational drug for advanced liver cirrhosis complications, aiming to raise $17.0 million.

Summary

• Option Therapeutics Inc. is a clinical-stage company developing BIV201 (continuous infusion terlipressin) for debilitating and life-threatening liver disease, including ascites and other complications of advanced liver cirrhosis.
• BIV201 has been granted FDA Fast Track and Orphan Drug designations for ascites (due to all etiologies except cancer).
• The company is conducting an Initial Public Offering (IPO) of 1,818,182 shares of common stock, with an anticipated price range of $10.00 to $12.00 per share (midpoint $11.00).
• Net proceeds from the IPO are estimated at approximately $17.0 million, or $19.7 million if the underwriters' over-allotment option is fully exercised.
• Proceeds will be used for working capital, general corporate purposes, a quarterly fee for support services from BioVie, and to fund the Phase 3 clinical trial for BIV201.
• Option Therapeutics will operate as a controlled company, with BioVie Inc. maintaining ownership of approximately 64% of outstanding common stock (or 60% if the over-allotment option is exercised).
• The company has a limited operating history, incurred a net loss of $1,223,839 for the year ended June 30, 2025, and $451,322 for the six months ended December 31, 2025, and expects to incur significant operating losses for the foreseeable future.
• Phase 2b study data for BIV201 showed at least a 30% reduction in ascites fluid during the 28 days after treatment initiation compared to the 28 days prior to treatment, with completers experiencing a 53% reduction, sustained at 43% over three months, versus a 3.1% increase in the standard of care group.
• BIV201 is a proprietary room-temperature stable liquid formulation of terlipressin, with patents issued in the U.S., Australia, China, Japan, Chile, and India, and seven pending applications.
• The estimated total addressable market for BIV201 therapy exceeds $2.3 billion, targeting approximately 190,000 unique patients annually in the United States with cirrhosis and ascites who experience at least one AKI per year.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a high-risk, early-stage biopharmaceutical IPO with significant capital needs and a history of operating losses, tempered by promising Phase 2 data and FDA designations for its lead candidate. The 'going concern' warning and early termination of a Phase 2 study due to cost are notable concerns.

Positives

• BIV201 has received FDA Fast Track and Orphan Drug designations for ascites, potentially expediting its development and regulatory review process.
• The proprietary room-temperature stable liquid formulation of terlipressin in a pre-filled syringe offers potential convenience and safety advantages over existing bolus administration products, which typically require refrigeration and lack a pre-filled syringe format.
• Phase 2b study data indicated a meaningful reduction in ascites fluid (30% overall, 53% for completers) in patients treated with BIV201 plus standard of care, contrasting with a 3.1% increase in the standard of care alone group.
• Cumulative safety data from Phase 2a and Phase 2b studies suggested continuous BIV201 infusion was well tolerated, with hyponatremia being the only serious adverse event related to terlipressin.
• The company holds multiple patents for BIV201's liquid formulations and methods of treating ascites in various countries, providing intellectual property protection.
• A large estimated total addressable market of over $2.3 billion in the U.S. for BIV201, targeting approximately 190,000 patients annually.
• The agreed-upon approach for the registrational Phase 3 trial could lead to earlier treatment of patients and expand market opportunity compared to the currently approved terlipressin product, Terlivaz.
• BIV201 has potential future applications in other life-threatening Orphan indications like HRS-AKI and bleeding esophageal varices, which command premium pricing (e.g., Terlivaz costs over $20,000 for six days of treatment for HRS-AKI).

Negatives

• The company has a limited operating history and has incurred significant operating losses since its inception, with expectations of continued losses for the foreseeable future.
• No products are approved for commercial sale, and no revenues have been generated to date, with no expected revenues in the near future.
• Substantial additional capital will be required beyond the IPO proceeds to finance operations, particularly to complete the Phase 3 trial and commercialization efforts.
• The company relies heavily on third parties for conducting clinical trials and manufacturing, introducing risks if these parties do not successfully carry out their duties or meet deadlines.
• Competition exists from other companies developing therapies for severe complications of advanced liver cirrhosis, as well as established treatments like diuretics and paracentesis.
• New investors will experience immediate and substantial dilution of $7.44 per share at the assumed IPO price of $11.00.
• The Phase 2b study was closed early due to cost considerations, and final data analysis was limited by the small sample size and confounded by a potential interaction with gabapentinoids.
• BIV201 does not qualify for New Chemical Entity (NCE) exclusivity due to the prior FDA approval of a powdered form of terlipressin (Terlivaz), potentially limiting market exclusivity.
• As a controlled company, BioVie will retain significant control (60-64% ownership), which may lead to conflicts of interest with other stockholders.
• The company will incur significant charges and incremental costs as a standalone public company following the separation from BioVie.
• The auditor's report includes an explanatory paragraph about the existence of substantial doubt concerning the company's ability to continue as a going concern.

Risks

• The company has a limited operating history, has incurred significant operating losses since inception, and expects to incur significant losses for the foreseeable future, with a high risk of never generating revenue or becoming profitable.
• Even if the IPO is successful, substantial additional capital will be required to finance operations, and a failure to obtain this capital could force delays, reductions, or termination of development programs or commercialization efforts.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• Reliance on third parties to conduct clinical trials means that if these parties do not successfully carry out their contractual duties or meet deadlines, regulatory approval or commercialization may be delayed.
• Development of pharmaceutical products is a time-consuming and uncertain process, and there is no assurance that product candidates will obtain regulatory approval.
• The company must comply with significant and complex government regulations, which may delay or prevent commercialization.
• Dependence on BioVie's management, and their loss or unavailability, could put the company at a competitive disadvantage.
• The biotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition, potentially making it difficult to compete with enterprises equipped with more substantial resources.
• There may be conflicts of interest among officers, directors, and stockholders due to their affiliations with BioVie.
• Inability to obtain or protect intellectual property rights relating to product candidates could have a material adverse effect on the business.
• The company has no recent history of operating as a standalone public company, and historical financial information may not reflect future results.
• The company may not achieve some or all of the expected benefits of the separation from BioVie, and the separation could adversely affect its business.
• BioVie will continue to control the direction of the business, and concentrated ownership may prevent other stockholders from influencing significant decisions.
• As a controlled company, the company will qualify for exemptions from certain NYSE corporate governance requirements, potentially reducing protections for stockholders.
• Significant charges will be incurred in connection with the separation and incremental costs as a standalone public company.
• Directors and executive officers may have actual or potential conflicts of interest because of their current BioVie positions or equity ownership in BioVie.
• Potential indemnification obligations to BioVie in connection with the separation could adversely affect the business.
• The terms of agreements with BioVie may be less favorable than if negotiated with unaffiliated third parties.
• The assets and resources acquired from BioVie in the separation may not be sufficient to operate as a standalone company.
• New investors will experience immediate and substantial dilution as a result of the IPO.
• Future sales and issuances of common stock could result in additional dilution and cause the stock price to decline.
• There is no liquid public market for the common stock, and one may not develop, leading to potential difficulty in selling shares.
• The market price and trading volume of the common stock may be volatile, potentially unrelated to operating performance.
• The company is an emerging growth company and a smaller reporting company, which may result in reduced reporting requirements that could make the stock less attractive to investors.
• No cash dividends are intended to be paid on common stock, so stockholders will only receive a return by selling shares.
• Anti-takeover provisions in organizational documents and Delaware law might discourage or delay acquisition attempts.
• Exclusive forum provisions in the amended and restated certificate of incorporation may discourage lawsuits against the company and its directors and officers.
• The auditor's report includes an explanatory paragraph about the existence of substantial doubt concerning the company's ability to continue as a going concern.

Future Outlook

The company expects to incur significant operating losses for the foreseeable future as it continues the clinical development of BIV201, seeks regulatory approval, and potentially commercializes the drug. Future operations are dependent on securing substantial additional financing, which may include equity sales, debt financings, or strategic collaborations. The company believes BIV201 has the potential to improve patient health and that the planned Phase 3 trial approach could lead to earlier treatment and expand market opportunities, with potential for future applications in other Orphan indications commanding premium pricing. The Board intends to establish a compensation committee and adopt a clawback policy in the future.

Management Comments

• "We believe BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis, and alcoholism."
• "We believe that BIV201, for continuous IV infusion, with its novel room temperature stable liquid formulation in a pre-filled syringe (and other container presentations), could potentially provide a superior terlipressin drug delivery system with improved safety versus the approved bolus administration products."
• "While a composite endpoint could obscure the response of a single definitive component of the endpoint, we believe the protocols planned secondary analysis of each component separately can sufficiently address this interpretation complexity."
• "The agreed-upon approach for conducting the registrational Phase 3 could lead to earlier treatment of patients and expand the market opportunity versus the currently approved terlipressin product in the U.S, Terlivaz."
• "Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions."
• "We believe that the terms and conditions of the management services agreement will be more favorable and cost effective to us than if we hired the full staff to operate the Company."

Industry Context

StockSavvy.ai notes that the liver cirrhosis market is substantial, with an estimated 4.5 million diagnosed individuals in the U.S. and 52,259 annual deaths, ranking 9th in causes of death. The prevalence of cirrhosis doubled between 2012 and 2018, driven by alcohol-related and MASLD cirrhosis, indicating a growing unmet medical need. The recent failure of Grifols, S.A.'s PRECIOSA Phase 3 study for albumin infusions in decompensated patients further underscores the urgent demand for effective treatments like BIV201. The estimated U.S. treatment costs for liver cirrhosis and complications exceed $5 billion annually, highlighting the significant economic burden and potential market for effective therapies.

Comparison to Industry Standards

• BIV201 is being developed as a continuous IV infusion of terlipressin, which contrasts with the FDA-approved Terlivaz (Mallinckrodt Hospital Products IP Limited), a lyophilized powder for bolus IV administration every six hours. Terlivaz carries a black box warning for serious or fatal respiratory failure and costs over $20,000 for six days of treatment for HRS-AKI.
• BIV201's proprietary room-temperature stable liquid formulation in a pre-filled syringe offers a potential convenience and safety advantage over Terlivaz and other global terlipressin products, which typically require refrigeration and lack a pre-filled syringe format.
• The Phase 2b study results for BIV201, showing a 30% reduction in ascites fluid (53% for completers) compared to a 3.1% increase in the standard of care group, suggest a potentially superior efficacy profile in managing ascites compared to current standard treatments.
• The company's strategy to target a broader ascites patient population, including those with recent AKI, and use a composite primary endpoint in Phase 3, aims to differentiate BIV201 from existing treatments and potentially expand its market opportunity beyond the more limited indication of Terlivaz.
• The failure of Grifols, S.A.'s PRECIOSA Phase 3 study for albumin infusions in decompensated patients highlights the high bar for success in this challenging patient population and the urgent need for novel therapies, positioning BIV201 as a potential solution in a market with significant unmet needs.

Management Changes

Corporate Governance

Legal Proceedings

• BioVie Inc. (the parent company) is subject to a purported shareholder class action lawsuit, Eric Olmstead v. BioVie Inc. et al., consolidated with Way v. BioVie Inc. et al., alleging material misrepresentations/omissions related to BioVie's business, operations, compliance, and prospects during December 7, 2022, through November 28, 2023. The court denied the motion to dismiss on March 27, 2025, and parties are in fact discovery.
• Three shareholder derivative lawsuits (Andrew Hulm, William Settel, Cline Wilkerson) were filed against BioVie's current and former officers and directors, piggy-backing on the securities class action, alleging breach of fiduciary duties, unjust enrichment, waste of corporate assets, gross mismanagement, and abuse of control. These were consolidated on September 29, 2025.
• Option Therapeutics Inc. will be indemnified under the separation agreement for these legal proceedings, as they remain BioVie's liability.
• Option Therapeutics Inc. is not otherwise currently subject to any legal proceedings or claims that are believed to have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• Option Therapeutics will enter into a separation agreement with BioVie, detailing the transfer of SpinCo Assets and assumption of SpinCo Liabilities, and establishing the framework for their post-separation relationship.
• Immediately prior to the IPO, Option Therapeutics will issue 3,181,718 shares of common stock to BioVie, resulting in BioVie owning approximately 64% (or 60% if over-allotment exercised) of Option Therapeutics' outstanding common stock.
• A management services agreement will be entered into, under which BioVie will provide management and administrative services to Option Therapeutics for a quarterly fee of $107,000 plus direct expenses. BioVie's executive officers will also serve as Option Therapeutics' executive officers.
• Option Therapeutics will grant BioVie and its affiliates certain registration rights for their common stock through a registration rights agreement, including unlimited piggyback rights and demand registration rights.
• BioVie will assign certain patents and patent applications related to BIV201 to Option Therapeutics via a patent assignment agreement.
• Option Therapeutics will assume the LAT Royalty Agreement, obligating it to pay a 5% royalty on net sales of BIV201 to LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc. (terminates December 31, 2036).
• Option Therapeutics will assume the Technology Transfer Agreement with the University of Padova, obligating it to pay a 5% royalty on net sales (capped at $200,000/year) of terlipressin products covered by specific patents (expiring 2036).
• Option Therapeutics will assume the Intellectual Property Rights Agreement with DOCUCHEM SLU, obligating payments of $25,000 upon U.S. patent issuance for terlipressin formulation and $50,000 annually if U.S. gross sales exceed $10,000,000.
• Directors and executive officers serving in dual roles for both companies may have actual or potential conflicts of interest, which are addressed by provisions in the amended certificate of incorporation renouncing corporate opportunities unless offered solely in their capacity as Option Therapeutics' director/officer.
• The separation agreement includes cross-indemnities, making Option Therapeutics financially responsible for its business liabilities and BioVie for its own, including BioVie's securities class action litigation.

Stakeholder Impact

• **Shareholders (New Investors)**: Will experience immediate and substantial dilution ($7.44 per share at $11.00 IPO price). Investment involves a high degree of risk due to limited operating history, expected losses, and significant capital requirements. BioVie's controlling ownership (60-64%) limits influence on significant decisions. No cash dividends are anticipated.
• **Shareholders (BioVie)**: Will retain a controlling interest (60-64%) in Option Therapeutics, allowing continued influence over its business direction. May benefit from the separation by creating a more efficiently valued equity currency and potentially realizing value from their retained shares.
• **Employees/Management**: Executive officers will serve dual roles for both BioVie and Option Therapeutics, with compensation paid by BioVie. Option Therapeutics will initially have no other directly employed staff. The 2026 Omnibus Equity Incentive Plan is established to attract, retain, and incentivize employees, directors, and consultants.
• **Customers/Patients**: BIV201 aims to address a significant unmet medical need for patients with advanced liver cirrhosis and ascites, potentially offering a superior and safer treatment option compared to existing therapies.
• **Creditors**: The 'going concern' warning raises concerns about the company's ability to meet its obligations without additional financing.
• **Suppliers/Third-Party Contractors**: The company relies heavily on third parties for clinical trials and manufacturing, and their performance is critical to the company's success and ability to bring BIV201 to market.

Next Steps

• Complete the Initial Public Offering (IPO) and list common stock on NYSE American under the symbol OPTN.
• Finalize protocol design for the Phase 3 clinical trial of BIV201.
• Initiate the Phase 3 clinical trial for BIV201, evaluating clinical benefit in patients with cirrhosis and ascites who have experienced a recent AKI.
• Post details on the clinical protocol to the National Clinical Trials website at the initiation of the trial.
• Seek regulatory approval from the FDA and international agencies for BIV201.
• Establish manufacturing, sales, and marketing arrangements with third parties if BIV201 is approved.
• Obtain adequate reimbursement by third-party payers for BIV201.
• Raise substantial additional capital to fund operations, including the Phase 3 trial and commercialization efforts.
• Potentially pursue marketing approvals for BIV201 in other life-threatening conditions due to liver cirrhosis, such as HRS-AKI and bleeding esophageal varices, which would require well-controlled clinical trials.
• Establish a compensation committee for the Board of Directors.
• Adopt a compensation recovery (Clawback) policy compliant with NYSE rules.

Key Dates

Recommendation

The company is an early-stage biopharmaceutical firm with a promising drug candidate (BIV201) that has received FDA Fast Track and Orphan Drug designations and shown positive Phase 2 results for a significant unmet medical need. However, the company has a limited operating history, no revenue, substantial ongoing losses, and a 'going concern' warning from its auditors. The IPO proceeds are insufficient to complete the Phase 3 trial, necessitating further capital raises, which will likely cause additional dilution. BioVie's controlling ownership and the early termination of a Phase 2 study due to cost are also significant concerns. Given the high risk associated with early-stage biotech, the substantial capital requirements, and the 'going concern' warning, a 'hold' recommendation is appropriate for investors to monitor the progress of the Phase 3 trial and the company's ability to secure necessary funding and achieve commercialization.

Keywords

Option Therapeutics, BIV201, Terlipressin, Liver disease, Cirrhosis, Ascites, Acute Kidney Injury, Hepatology, Clinical stage, Biopharmaceutical, IPO, SEC filing, Orphan Drug, Fast Track, BioVie, Drug development, Phase 3 trial, Pharmaceuticals, Biotech, Healthcare, Medical, Investment